Contact Congress about H.R. 1393: To amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.

Some experimental drugs could move from Schedule I to Schedule II faster. The bill ties that step to Food and Drug Administration decisions for serious diseases. It also lets the government move the drug back if it no longer qualifies.

Modern Action explains what the legislation does, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

To amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes. is a House bill in Congress.

Who this affects: This bill mainly affects researchers, drug companies, federal drug regulators, and patients in limited treatment programs for serious diseases. It could change how some experimental drugs are studied, controlled, and moved between federal drug schedules.

Why this matters: This bill matters because Schedule I rules can make drug research and limited medical access harder. Moving a drug to Schedule II can make study and tightly controlled use easier, while still keeping strong federal controls. The bill may make those decisions more predictable by tying them to Food and Drug Administration actions. But it could also move some drugs based on early evidence, and the drug could later move back to Schedule I.

Key provisions in H.R. 1393

• The bill defines “currently accepted medical use with severe restrictions” for the first time. This definition would become part of the Controlled Substances Act, the main federal drug-control law.
• The bill applies to certain experimental drugs. These drugs must have Food and Drug Administration waivers under federal food, drug, biologic, or public health laws.
• A drug can qualify if the Food and Drug Administration calls it a breakthrough therapy. It can also qualify if the agency allows expanded access for a serious or life-threatening disease with no good existing treatment.
• A drug can lose this status if its expanded access use is put on clinical hold. That only applies when no other expanded access program exists and the drug is not a breakthrough therapy.
• A fully approved drug cannot use this limited-use pathway. Once the Food and Drug Administration approves it through normal drug or biologic rules, other scheduling rules must apply.

How Modern Action helps you take action on H.R. 1393

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about H.R. 1393

What is H.R. 1393?

Some experimental drugs could move from Schedule I to Schedule II faster. The bill ties that step to Food and Drug Administration decisions for serious diseases. It also lets the government move the drug back if it no longer qualifies.

How do I support or oppose H.R. 1393?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about H.R. 1393?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

How does Modern Action help me act on H.R. 1393?

Modern Action gives you bill-specific context, lets you choose support, opposition, or changes, and drafts a message from your position and reasons.